MannKind grants Colby rights to immunotherapy programs

MannKind Corp. (NASDAQ:MNKD) granted Colby Pharmaceutical Co. (San Jose, Calif.) exclusive, worldwide rights to develop and commercialize MannKind's MKC1106 active immunotherapy programs, including intra-lymph node delivery technologies. MannKind is eligible for up to $140 million in an upfront and milestone payments, plus tiered royalties. ...